47.90
+0.65
(1.38%)
Real-time:
9:08am BST
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 46.09 - 47.90 |
| 52 week | 39.39 - 85.00 |
| Open | 46.09 |
| Vol / Avg. | 5,551.00/105,476.00 |
| Mkt cap | 85.03M* |
| P/E | 11.74 |
| Div/yield | - |
| EPS | 0.04* |
| Shares | 177.51M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
Jun 3, 2013
Interim 2013 GW Pharmaceuticals PLC Earnings Conference Call -
May 21, 2013
Interim 2013 GW Pharmaceuticals PLC Earnings Release
Apr 12, 2013
GW Pharmaceuticals PLC General Meeting
|
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 0.96% | 7.52% |
| Operating margin | -36.62% | 3.15% |
| EBITD margin | - | 5.43% |
| Return on average assets | 0.57% | 6.07% |
| Return on average equity | 1.17% | 12.81% |
| Employees | 177 | - |
| Carbon Disclosure Rating | - | - |
Address
Porton Down Science Park
SALISBURY, ENG SP4 0JQ
United Kingdom - Map
+44-1980-557000 (Phone)
+44-1980-557111 (Fax)
SALISBURY, ENG SP4 0JQ
United Kingdom - Map
+44-1980-557000 (Phone)
+44-1980-557111 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
GW Pharmaceuticals plc is a United Kingdom-based company. The Company is engaged in the research, development and commercialization of a range of cannabinoid prescription medicines to meet patient needs in a range of medical conditions. The Company is developing a portfolio of cannabinoid medicines, of which the main product is Sativex, an oromucosal spray for the treatment of Multiple Sclerosis (MS) symptoms, cancer pain and neuropathic pain. The Company operates in three segments: Sativex Commercial, Sativex Research and Development and Pipeline Research and Development. The Company�s wholly owned subsidiaries include GW Pharma Limited, G-Pharm Limited, Cannabinoid Research Institute Limited, Guernsey Pharmaceuticals Limited and GWP Trustee Company Limited.
Officers and directors
| Geoffrey W. Guy | Executive Chairman of the Board | |
| Adam David George | Finance Director, Group Financial Controller, Company Secretary, Executive Director | |
| Christopher John Tovey | Chief Operating Officer, Executive Director | |
| Justin Gover | Managing Director, Executive Director | |
| Stephen Wright M.D. | Research & Development Director, Executive Director | |
| James Julian Noble | Non-Executive Deputy Chairman of the Board, Senior Independent Director | |
| Cabot Brown | Non-Executive Director | |
| Thomas Gerard Lynch | Non-Executive Independent Director |
